A Case of Cholestatic Liver Involvement Secondary to Amyloid Light Chain Amyloidosis With New-Onset Hypercholesterolemia and Elevated Gamma-Glutamyltransferase Level

Amyloid light chain (AL) amyloidosis is a rare disorder caused by the deposit of misfolded light chain proteins. AL amyloidosis causes multiple organ involvement and rarely causes fatal liver failure. We present a 68-year-old man who showed cholestatic liver injury and was diagnosed with AL amyloido...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2023-08, Vol.15 (8)
Main Authors: Nakano, Yuta, Kawamoto, Ryosuke, Ito, Eisaku, Matukawa, Kayoko
Format: Article
Language:English
Subjects:
Amyloidosis
Antibodies
Antigens
Ascites
Biopsy
Blood
Bone marrow
Case reports
Cholesterol
Creatinine
Hematology
Hemoglobin
Hepatitis C
High density lipoprotein
Immunoglobulins
Internal Medicine
Kidneys
Leukocytes
Light
Lipoproteins
Liver
Microscopy
Multiple myeloma
Oncology
Phosphatase
Proteins
Statins
Thyroid gland
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Amyloid light chain (AL) amyloidosis is a rare disorder caused by the deposit of misfolded light chain proteins. AL amyloidosis causes multiple organ involvement and rarely causes fatal liver failure. We present a 68-year-old man who showed cholestatic liver injury and was diagnosed with AL amyloidosis. Due to rapidly progressing cholestatic liver involvement, the patient died five days after the renal biopsy. Preclinically, there was hypercholesterolemia, and levels of gamma-glutamyltransferase (GGT) were elevated. Previous studies have suggested hypercholesterolemia and elevated GGT levels in patients with AL amyloidosis and liver involvement; however, its clinical relevance remains unknown. Our report suggests that in addition to serum kappa/lambda, the combination of new-onset GGT level elevation and hypercholesterolemia could be preclinical characteristics of cholestatic liver involvement in AL amyloidosis.
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.44001